0.750
-0.02 (-1.97%)
| Previous Close | 0.765 |
| Open | 0.768 |
| Volume | 363,739 |
| Avg. Volume (3M) | 1,015,470 |
| Market Cap | 93,550,400 |
| Price / Sales | 0.690 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Profit Margin | -61.72% |
| Operating Margin (TTM) | -65.72% |
| Diluted EPS (TTM) | -1.14 |
| Quarterly Revenue Growth (YOY) | 13.90% |
| Current Ratio (MRQ) | 3.62 |
| Operating Cash Flow (TTM) | -130.34 M |
| Levered Free Cash Flow (TTM) | -79.55 M |
| Return on Assets (TTM) | -31.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Karyopharm Therapeutics Inc. | Mixed | Bullish |
Stockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.33 |
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.07% |
| % Held by Institutions | 56.69% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Oct 2024 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Sep 2024 | Announcement | Karyopharm to Participate at Upcoming Investor Conferences |
| 03 Sep 2024 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Aug 2024 | Announcement | Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress |
| 01 Aug 2024 | Announcement | Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 31 Jul 2024 | Announcement | Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |